Posts by Stephan Müller:
leadXpro AG and the University of Zurich (UZH) collaborate to generate sybodies as molecular discovery tools, therapeutic lead compounds and diagnostic reagents against disease-relevant membrane protein targets.
leadXpro AG and InterAx Biotech AG, join forces to discover and optimize new drug lead molecules targeting G-protein coupled receptors.
The paper reports an efficient method to generate multiple co-structures of the A2A G protein-coupled receptor (GPCR) with small-molecules from a single preparation of a thermostabilised receptor crystallised in Lipidic Cubic Phase (LCP)
leadXpro AG scientists explore the utility of cutting-edge X-ray technologies for the discovery of new therapeutics.
Creoptix and leadXpro AG announce the selection of the Creoptix WAVE technology by leadXpro to strengthen its capabilities for drug discovery aimed at identifying and optimizing drug candidates directed against challenging membrane protein drug targets.